US20050029181A1 - Automated processing of a biological component - Google Patents
Automated processing of a biological component Download PDFInfo
- Publication number
- US20050029181A1 US20050029181A1 US10/635,181 US63518103A US2005029181A1 US 20050029181 A1 US20050029181 A1 US 20050029181A1 US 63518103 A US63518103 A US 63518103A US 2005029181 A1 US2005029181 A1 US 2005029181A1
- Authority
- US
- United States
- Prior art keywords
- biological fluid
- chamber
- fraction
- biological
- cassette
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
Definitions
- the present invention relates to an automated process for purification and concentration of a biological component and, in particular, the purification and concentration of plasminogen, which then can be converted to plasmin for use in surgical or therapeutic procedures.
- Plasminogen is exemplary of a blood component that is separated from a patient's own blood and reintroduced into the patient.
- Plasminogen is a component of the fibrolytic system and is the plasma-protein precursor of plasmin, a serine protease. Plasmin is well known to function in fibrinolysis and fibrinogenolysis, as well as digesting factor IX a , and the activation of zymogens, among its many functions.
- the injection of plasmin into a human eye has been shown to induce posterior vitreous detachment, as detailed in U.S. Pat. No. 5,304,118.
- a rapid manual method for purification of plasminogen utilized an affinity cartridge under syringe pressure to selectively bind a desired blood component.
- the affinity cartridge was then washed with an equilibration buffer followed by injecting an elution buffer therethrough containing a release agent for the desired blood component.
- This method is detailed in U.S. Pat. No. 6,207,066 and is capable of delivering active plasmin from a blood sample within tens of minutes.
- this method has met with limited acceptance owing to the manual steps required and the variability introduced.
- the present invention overcomes the previously known disadvantages of the previously known biological component separation methods by providing an automated separation, purification, and concentration of a biological component, specifically for separating a blood component for autologous usage.
- the automated system includes a programmable controlled instrument that interacts with a sterile disposable cassette and tubing set.
- the disposable cassette consists of chambers, fluid paths, and valves.
- the cassette houses at least one chamber, which contains the desired blood component affinity material.
- the affinity material of the type, which binds with the desired biological component, is prepared prior to the time of use.
- L-lysine (or other protein binding component) is covalently attached to silica which has been epoxy activated.
- Silica is a material that can withstand very high pressure and still maintain its shape. This matrix yields low backpressure and high flow rates.
- One to five cubic centimeters (cc) of the lysine-silica are loaded into a cassette chamber.
- An optimal second chamber housed in the cassette contains a molecular exclusion filtration media.
- the filtration media is of the type which allows large molecules like the desired biological component to pass through the chamber unimpeded, yet retards the passage of smaller molecular weight molecules like those used for competitive elution of the blood component from the affinity chamber. This results in a molecular separation.
- concentration media chamber in the cassette concentrates the desired biological component solution.
- concentration media of the type which is made of cross-linked dextran with liquid absorbing and molecular exclusion properties.
- Additional chambers are optionally included in the cassette to provide solution storage and transfer during the process.
- Other chambers can provide for the conversion of the desired biological component to its active state and provide a space for the resultant preparation to be assayed for final activity determination.
- the cassette incorporates fluid paths connecting inlet and outlet fluids to the various chambers.
- the cassette provides the means to valve the flow of fluids to and around the cassette chambers, in addition to controlling fluids to waste and collection.
- the cassette has at least one inlet and one outlet port that has tubing connected to the port.
- the other end of the tubing is connected to a fluid bag or bags.
- the inlet tubing allows the fluids, like equilibration buffer, plasma or plasma solution, and/or competitive elution solution, to be brought into the cassette and selectively to the cassette chambers.
- the outlet tubing allows fluids to be selectively expelled from the cassette and to a fluid waste collection bag.
- the instrument contains a programmable controller of the type which is of electronic, pneumatic, or mechanical (cam) driven or a combination thereof.
- the controller receives inputs, such as from pushing the start button, and delivers outputs, such as turning a pump on and off, closing and opening valves, and signaling procedure completion.
- blood is first drawn from the patient and the blood plasma is separated from the cellular blood elements using conventional methods, such as centrifugation. After centrifugation, the blood plasma containing the blood component is retained and the cellular blood elements are discarded. The blood plasma is collected into a syringe and transferred to the plasma fluid bag attached to the cassette. A second fluid bag attached to the cassette is loaded with equilibration buffer and a third fluid bag is loaded with an elution buffer.
- the cassette is loaded into the programmable controlled instrument and the fluid bags are hung on their appropriate hooks.
- the power to the instrument is turned on and the start button is pushed to initialize the controller.
- the controller now orchestrates the pump, valves, and solenoids to route the correct fluid through the various chambers at the appropriate time and in the appropriate volumes, in order to yield the desired component in a desired concentration in a collection vial at the conclusion of the process.
- a known amount of an activator is then added to the eluted blood component to obtain the desired subcomponent, such as plasmin.
- the blood component or subcomponent is then used as desired in the surgical or therapeutic procedure.
- FIG. 1 is an isometric view of the system including the programmable controlled instrument and disposable cassette assembly with attached fluid lines;
- FIG. 2 is a schematic diagram illustrating the components of the preferred embodiment of the present invention.
- the present invention has utility in the processing of a biological fluid to purify a component therefrom.
- the present invention will be described with respect to automatically separating the blood component plasminogen from blood plasma.
- the plasminogen is subsequently converted into plasmin and used for surgical and/or therapeutic procedures, such as a vitrectomy and/or vitreous liquefaction.
- other blood components are readily separated from blood utilizing the method of the present invention. These other blood components illustratively include fibrin, apolipoprotein, and antibodies.
- component separations illustratively include urokinase from urine, nerve growth factor from cerebrospinal fluid, and various components from cell growth media or whole blood.
- System 1 is comprised of two distinct components, a programmable instrument 2 , and a sterile single-use disposable cassette assembly 3 .
- the programmable instrument 2 contains a programmable controller having a user interface 20 , solenoid and/or pneumatic valve actuators 50 , and a pump 19 .
- a control panel 20 provides a user interface for programmable controller functions such as to power the instrument, start the preparation process, and monitor the parameters of the process.
- the disposable cassette assembly 3 is typically made of plastic such as polypropylene, polycarbonate, or polyvinyl chloride, and includes a cassette 4 that houses at least one internal chamber and has at least one inlet port 13 and one outlet port 17 .
- the inlet port 13 is connected to a manifold 21 through inlet pump chamber tubing 31 .
- the manifold 21 is in fluid communication with solution containers of plasma 8 , buffer 9 , and elution solution 10 .
- the solution containers are sterile bags conventional to the blood storage art.
- the outlet port 17 is in fluid communication with a waste collection bag 12 via outlet tubing 11 .
- the cassette 4 is placed into a receiving pocket 18 of programmable instrument 2 , where it is selectively held therein.
- FIG. 2 shows the preferred system components in schematic form.
- Cassette 4 is represented by the dotted line box shown in FIG. 2 including a rigid housing 54 .
- the cassette 4 includes affinity media chamber 22 , the chamber 22 enclosing affinity media 24 .
- An amino acid, such as L-lysine, is affixed to the solid support offered by the affinity media 24 .
- Affinity media chamber 22 has an inlet 26 and an outlet 28 such that all liquid injected into the inlet 26 passes through the affinity media 24 and exits through the outlet 28 .
- the amino acid L-lysine has a high affinity to selectively adsorb the blood component plasminogen from blood plasma.
- the lysine (L-lysine monohydrochloride, Sigma Chemical (L-6027)) is bound to the affinity media by conventional methods and then packed into the chamber 22 .
- the affinity media chamber 22 is made of polypropylene with polyethylene frits.
- other species are readily bound to the affinity media 24 to selectively adsorb blood components. These species illustratively include antibodies specific to a particular blood component; platelet derived growth factor or other hormones.
- heparin is a mucopolysaccharide sulfuric acid ester that is found in liver tissue.
- Heparin is active as a ligand to selectively bind fibroblast growth factor, vascular endothelial growth factor (VEGF), and platelet derived growth factor (PDGF) from cell culture media. Heparin also is active to selectively bind proteins from whole blood or plasma that are involved in the coagulation cascade such as thrombin.
- VEGF vascular endothelial growth factor
- PDGF platelet derived growth factor
- the chamber 22 typically contains 1 to 5 cc packed volume of affinity media such as L-lysine bound to a rigid support such as epoxy-activated silica beads.
- affinity media such as L-lysine bound to a rigid support such as epoxy-activated silica beads.
- 2 to 4 cc of affinity medium is utilized herein.
- Other alternative beads can include a ceramic matrix illustratively including alumina or titania with lysine attached via an epoxy-activated linkage.
- the affinity media is required to withstand the application of pressure necessary for performing an inventive elution throughput without collapsing.
- the pressure operative herein is defined to be at least the pressure exerted by a roller pump, syringe pump, or other pump mechanisms against the back pressure induced by the affinity media. Pressures generated herein are typically 1 to 10 atmospheres.
- the epoxy-activated silica beads operative herein are manufactured by Waters Corporation. Such beads typically have a diameter of 40 ⁇ m, a pore size of 50 nm and a binding capacity of 3- 7 ⁇ moles of lysine per (ml) of packing material.
- Cassette 4 also has a gel media chamber 30 that contains gel filtration media 32 , composed of cross-linked dextran beads.
- the gel filtration media 32 performs molecular size exclusion.
- the large blood component plasminogen passes through the gel media 32 comparatively unimpeded while the smaller elution molecules such as epsilon aminocaproic acid enter the pores of the gel media beads and are slowed in traversing the gel media to create a separation.
- the gel filtration medium is G-25 fine Sephadex (Amersham Biosciences). It is appreciated that other gel media are operative to filter a desired blood plasma component based upon factors including blood component molecular weight.
- the gel media chamber 30 typically contains 1.0 to 2.5 gms of dry gel beads 32 that swell when hydrated to fill a chamber volume of between 3.5 to 8.8 ml.
- the gel media chamber 30 is made of polypropylene with polyethylene frits.
- an ion exchange chromatography media chamber (Sigma Aldrich, Amersham, Waters) is used to molecularly filter the desired blood plasma component based on molecular charge and ionic strength.
- the aminocaproic acid molecule forms an ionic bond to the media, displacing a hydrogen ion.
- the plasminogen then freely passes through the media.
- the collected fraction may have to be adjusted for pH as a result of the ionic exchange.
- the cassette 4 also includes collection chamber 34 having movable plunger 36 .
- Collection chamber 34 allows the collection of the plasminogen rich fraction from the elution curve exiting the gel media chamber 30 .
- the collected fraction volume typically ranges from 1.0 ml to 5.0 ml for the processing of 0.5 to 2.0 milligrams of plasminogen.
- the cassette 4 also includes a concentration chamber 38 that includes a filter net 40 (shown in FIG. 2 ), movable plunger 42 , and concentration media 44 .
- the concentration media 44 preferably are cross-linked dextran beads.
- the preferred concentration media is commercially available as dry Sephadex G-50 (Amersham Biosciences), D-salt polyacrylamide gel with a 6,000 Dalton exclusion limit (Pierce Biotechnology), or similar material.
- the dry quantity of concentration media 44 absorbs a known quantity of solvent thereby concentrating the plasminogen in the remaining solvent.
- the quantity of concentrating media is selected to impart a plasminogen concentration of at least two. More preferably, plasminogen is concentrated by a factor of between 3 and 10.
- 2.6 cc of eluted buffer and plasminogen yields 0.45 ml upon contacting 0.34 grams of dry G-50 Sephadex thereby increasing plasminogen concentration to a final concentration of 0.9-3.0 milligrams per milliliter.
- the concentrating of a blood component according to the present invention appears to rely on the ability of an immobilized substance such as a Sephadex filtration medium to absorb a well-defined quantity of a solution without absorbing or binding the plasminogen at a higher rate than volume concentration.
- Flexible tubing 48 is used within the cassette 4 to provide fluid communication between the inventive chambers.
- flexible tubing 48 functions as a valve when force is applied.
- filters, collection vial(s), or test chambers optionally are isolated.
- Solenoid and/or pneumatic valve actuators are positioned in instrument 2 such that piston rods 50 align with openings 52 in cassette 4 overlying predetermined sections of tubing 48 .
- the openings 52 allow the piston rods 50 to linearly travel and compress the flexible tubing 48 against the rigid housing 54 of cassette 4 . Valving action is preferably signaled by the programmable controller.
- the inventive process starts with a predetermined amount of blood, for example 48 cc, being removed from the patient in any conventional fashion such as by syringe or vacuum collection tubes containing an anticoagulant.
- a predetermined amount of blood for example 48 cc
- the amount of blood removed from the patient varies, depending upon the final amount of the desired blood component required.
- the blood plasma is separated from the cellular blood elements in any conventional fashion, such as by centrifuging.
- the blood is centrifuged at 1000 g for ten minutes at 25° C.
- the plasma is then collected in a sterile syringe. Typically, 10 to 30 cc of plasma is collected.
- Fluid bag container 9 is filled with a sterile equilibrium buffer plasma, such isotonic potassium phosphates buffer, balanced salt solution, or a dilute balanced salt solution, in a volume of between 50 ml and 250 ml.
- Fluid bag 10 is filled with a competitive elution solution, such as epsilon aminocaproic acid and potassium phosphate buffer, in volume of between 5 ml and 20 ml and a concentration of between 0.5 mg/ml and 10.0 mg/ml.
- the plasma and/or elution solution remain in syringes that are connected to the tubing in lieu of a fluid bag.
- Disposable cassette assembly 3 is loaded into the programmable instrument 2 .
- Solution bags 8 , 9 , and 10 are hung so as to gravity feed the instrument 2 .
- Tubing lines 5 , 6 , and 7 are placed into corresponding slots 60 , 62 , 64 , respectively.
- Manifold 21 is placed in recess 66 .
- Pump chamber 31 is fed into roller pump 19 and cassette 4 is locked in place into instrument pocket 18 .
- Outlet tube 11 is placed in slot 58 and fluid bag 12 is positioned to collect the fluid waste transmitted by outlet tube 11 .
- the inventive sequence of events begins with instrument 2 being energized through the user interface control panel 20 .
- Table 1 provides a step-by-step breakdown of the preparation process indicating fluid movements and valving of the present invention with respect to FIGS. 1 and 2 .
- Table 1 presumes prior blood draw and fluid bag filling.
- Step 1 involves the delivery of equilibrium buffer for pre-washing of the affinity media, hydrating and washing the gel media, and delivering the passed fluids to waste.
- the buffer is drawn from fluid bag 9 through tubing 6 and through open valve V 1 .
- the buffer flows into manifold 21 and through pump chamber 31 driven by pump 19 , through open valve V 2 and into affinity media chamber 22 .
- the buffer continues through the affinity media chamber 22 pre-washing and wetting the affinity media 24 , then exiting chamber 22 flowing through open valve V 3 and into gel filtration media chamber 30 .
- the buffer is absorbed by the dry gel media 32 , swelling the beads and expanding to fill chamber 30 and washing of the gel media 32 after swelling.
- Buffer continues to be pumped through chamber 30 until it exits and flows through open valve V 4 , through tubing 11 and into waste fluid bag 12 . All other valves in the system are closed at this time. Buffer continues to be pumped through at Step 1 until a predetermined time and/or volume has been reached and the programmable controller stops the pump 19 and switches the valve sequence to Step 2 .
- Step 2 delivers the plasma through the affinity media 24 , where the lysine ligand selectively binds to the desired blood component, which for illustrative purposes is plasminogen.
- the plasma is draw out of fluid bag 8 through tubing 7 and through open valve V 5 .
- the plasma flows into manifold 21 and through pump chamber 31 driven by pump 19 , through open valve V 2 and into affinity media chamber 22 .
- the plasma flows out of chamber 22 and through open valve V 7 .
- Plasma continues to flow out through tubing 11 and into waste fluid bag 12 . All other valves in the system are closed at this time.
- Plasma continues to be pumped through at Step 2 until a predetermined time, volume, and/or a sensor determined condition has been reached. Then, the programmable controller stops the pump and switches the valve sequence to Step 3 .
- Step 3 delivers equilibrium buffer to the affinity media chamber 22 to wash the plasma from the chamber 22 along with any unbound proteins, leaving only the bound blood component, namely plasminogen.
- Buffer is drawn out of fluid bag 9 through tubing 6 and through open valve V 1 .
- the buffer flows into manifold 21 and through pump chamber 31 driven by pump 19 , through open valve V 2 and into affinity media chamber 22 .
- the buffer flows out of chamber 22 and through open valve V 7 .
- the buffer continues to flow out through tubing 11 and into waste fluid bag 12 . All other valves in the system are closed during Step 3 as detailed in Table 1. Buffer continues to be pumped through at Step 3 until a predetermined time, volume, and/or a sensor determined condition has been reached. Then, the programmable controller stops the pump and switches the valve sequence to Step 4 .
- Step 4 involves the displacement of the equilibrium buffer from the affinity media chamber 22 and gel chamber 30 , and the elution of the plasminogen from the affinity media 24 with a competitive binding solution, such as epsilon aminocaproic acid also occurs in the course of Step 4 .
- Elution solution is withdrawn from fluid bag 10 through tubing 5 and through open valve V 6 .
- the elution solution flows into manifold 21 and through pump chamber 31 driven by pump 19 , through open valve V 2 and into affinity media chamber 22 .
- the elution solution continues through the affinity media chamber 22 flushing the buffer and unbinding the plasminogen, then exiting chamber 22 flowing through open valve V 3 and into gel filtration media chamber 30 .
- the solution is molecularly filtered by the gel filtration media 32 by allowing the large molecular weight plasminogen to flow through and the low molecular weight elution molecule to be retarded by entering the pores of the swollen gel beads.
- Elution solution continues to be pumped through gel media chamber 30 until it exits and flows through open valve V 4 , through tubing 11 and into waste fluid bag 12 . All other valves in the system are closed at this time.
- Elution solution continues to be pumped through at Step 4 until a predetermined time, volume, and/or a sensor determined condition has been reached and the programmable controller stops the pump 19 and switches the valve sequence to Step 5 .
- the controller preferably allows a dwell time between the elution solution to elute more of the plasminogen from the lysine. Dwell time appears to increase the eluted peak height and therefore the eluted protein.
- the dwell time is in the range of 5 to 30 minutes.
- Step 5 involves the continuation of the plasminogen elution process, with preferably the elution curve staged such that the highest concentration of plasminogen can be collected in a single fraction. It is appreciated that other collection profiles are possible according to the present invention.
- Elution solution is withdrawn from fluid bag 10 through tubing 5 and through open valve V 6 .
- the elution solution flows into manifold 21 and through pump chamber 31 driven by pump 19 , through open valve V 2 and into affinity media chamber 22 .
- the elution solution will continue through the affinity media chamber unbinding the plasminogen, then exiting chamber 22 flowing through open valve V 3 and into gel filtration media chamber 30 . Gel filtration media chamber 30 continues to separate the plasminogen from the eluent.
- the plasminogen solution exits chamber 30 and flows through open valve V 12 and into collection chamber 34 .
- the pressure of the incoming fluid displaces plunger 36 of chamber 34 while valves V 1 , V 14 , and V 15 are open so that the air in the system moved by the displaced collection plunger 36 exits the system through filter 60 .
- Elution solution continues to be pumped through at Step 5 until a predetermined time, volume, and/or a sensor determined condition has been reached and the programmable controller stops the pump and switches the valve sequence to Step 6 .
- Steps 4 and/or 5 can be independently controlled by monitoring the component concentration exiting gel filtration media chamber 30 .
- a spectrophotometric light generator and detector at a wavelength overlapping a component absorption, which for plasminogen is illustratively 280 nm, not shown, is adapted to detect the change in absorption in the fluid stream.
- the absorption signal correlating to the protein concentration.
- the controller is programmed to switch the sequence of the valves when a predetermined protein concentration is reached, in order to insure consistent capture of the protein peak of the elution profile.
- Step 6 involves the moving of the collected fraction volume of, for example, approximately 2.6 ml of plasminogen solution from collection chamber 34 to concentration chamber 38 .
- concentration of the plasminogen solution will be increased by removing a percentage of the aqueous from the solution by concentration media 44 .
- Buffer is drawn from fluid bag 9 through tubing 6 and through open valve V 1 .
- the buffer flows into manifold 21 and through pump chamber 31 driven by pump 19 , and through open valves V 9 and V 11 .
- the buffer is used as a hydraulic fluid to displace plunger 36 in collection chamber 34 and move the plasminogen solution out of the chamber 34 .
- the plasminogen solution moves out of collection chamber 34 through open valve V 13 and into concentration chamber 38 , displacing plunger 42 .
- valve V 15 is open so that the air moved by displaced plunger 42 of chamber 38 is vented from the system through filter 60 .
- Step 7 involves the movement of a concentrated volume of approximately 0.5 ml, based on 2.6 ml plasminogen volume in Step 6 of plasminogen solution from the concentration chamber 38 to final collection vial 62 .
- Collection vial 62 is optionally incorporated into cassette 4 or may be added to the system during setup.
- Buffer is drawn from fluid bag 9 through tubing 6 and through open valve V 1 .
- the buffer flows into manifold 21 and through pump chamber 31 driven by pump 19 , and through open valves V 9 and V 14 .
- the buffer is being used as a hydraulic fluid to displace plunger 42 in chamber 38 and move the concentrated plasminogen solution out of the chamber 38 .
- the pressure reaches a preselected level, the plasminogen solution moves out of collection chamber 38 through open valve V 10 , through filter 64 , through piercing device 66 and into collection vial 62 .
- the collected plasminogen is available for a variety of uses and may be converted or activated to plasmin by the addition of an activator such as streptokinase or urokinase.
- an activator such as streptokinase or urokinase.
- the activator is placed in the vial prior to attaching it to cassette 4 , so conversion occurs as the final concentrated plasminogen is expressed into the vial 62 .
- the conversion of plasminogen to plasmin occurs in 5-15 minutes at room temperature.
- the plasmin is now ready for use such as for injection into the eye, or other surgical or research applications.
- urokinase is isolated from urine as an activator of plasminogen to the enzyme plasmin.
- a disposable cassette with a single chamber contains affinity media such as an antibody or antibody fraction bound to a rigid support, such as epoxy-activated silica bead.
- the antibody illustratively including goat anti-human urokinase, Monosan PS075 (Sanbio, The Netherlands).
- the affinity media is washed with buffer then urine is pumped through the affinity chamber.
- the urokinase selectively binds to the antibody and then the affinity chamber is flushed of the residual urine and urine constituents.
- the elution is performed with an acidic citrate buffer that is introduced to the affinity chamber to unbind the urokinase.
- the peak of the eluted urokinase is collected in a collection vial where neutralization optionally occurs if desired for a particular purpose.
- Active plasmin quantification involves conventional techniques such as placing a drop of plasmin solution onto a piece of filter paper treated with a synthetic substrate (D-val-leu-lys-pnitroanilide dihydrochloride, Sigma V-0882). Cleavage of the substrate produces a bright yellow color the intensity of which correlates with the presence of plasmin.
- a spectrophotometric assay based upon the difference between initial and final optical absorbance multiplied by a constant for the cleavage of the synthetic substrate (D-val-leu-lys-pnitroanilide dihydrochloride) measured at a wavelength of 405 nanometers, is employed.
- Absorption studies are performed by adding 950 ⁇ l of lysine buffer and 250 ⁇ l of substrate to a cuvette and zeroing the initial absorbance. 50 ⁇ l of plasmin is then added and the absorbance one minute later is measured as the final absorbance.
- the above-described separation of the blood component plasminogen and its subsequent conversion into plasmin is accomplished in the matter of tens of minutes in the operating room or laboratory.
- the automation allows several plasmin preparations to be performed simultaneously by a single clinical technician.
- the sterile single use cassette assembly provides a closed system of biologic preparation.
- Patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are incorporated herein by reference to the same extent as if each individual patent or publication was specifically and individually incorporated herein by reference.
Abstract
Description
- The present invention relates to an automated process for purification and concentration of a biological component and, in particular, the purification and concentration of plasminogen, which then can be converted to plasmin for use in surgical or therapeutic procedures.
- With concerns about identifying ever-changing strains of HIV, hepatitis, and other blood born pathogens, the use of blood bank whole blood as a source for blood components in non-emergency surgical procedures is disfavored. As a result, it is advantageous to draw blood from a patient, extract the needed blood component, and then reintroduce the blood component into the patient during a surgical procedure. Plasminogen is exemplary of a blood component that is separated from a patient's own blood and reintroduced into the patient.
- Plasminogen is a component of the fibrolytic system and is the plasma-protein precursor of plasmin, a serine protease. Plasmin is well known to function in fibrinolysis and fibrinogenolysis, as well as digesting factor IXa, and the activation of zymogens, among its many functions. The injection of plasmin into a human eye has been shown to induce posterior vitreous detachment, as detailed in U.S. Pat. No. 5,304,118.
- While methods of isolating plasminogen are well known to the art, these methods require considerable time, skill, and expensive equipment that precluded plasmin extraction and isolation as a routine adjunct to a surgical procedure or therapy. As a result, the benefits that plasmin offers as an adjunct to surgical and/or therapeutic procedures is limited to a few medical institutions. Exemplary of these time-consuming plasminogen purification procedures are U.S. Pat. Nos. 3,943,245; 5,371,007 and Castellino, Methods of Enzy., Vol. 80, 265-337 (1981).
- A rapid manual method for purification of plasminogen, as disclosed in the art, utilized an affinity cartridge under syringe pressure to selectively bind a desired blood component. The affinity cartridge was then washed with an equilibration buffer followed by injecting an elution buffer therethrough containing a release agent for the desired blood component. This method is detailed in U.S. Pat. No. 6,207,066 and is capable of delivering active plasmin from a blood sample within tens of minutes. However, this method has met with limited acceptance owing to the manual steps required and the variability introduced. Thus, there exists a need for an automated process for purifying a biological component.
- The present invention overcomes the previously known disadvantages of the previously known biological component separation methods by providing an automated separation, purification, and concentration of a biological component, specifically for separating a blood component for autologous usage. The automated system includes a programmable controlled instrument that interacts with a sterile disposable cassette and tubing set.
- The disposable cassette consists of chambers, fluid paths, and valves. The cassette houses at least one chamber, which contains the desired blood component affinity material. The affinity material of the type, which binds with the desired biological component, is prepared prior to the time of use. L-lysine (or other protein binding component) is covalently attached to silica which has been epoxy activated. Silica is a material that can withstand very high pressure and still maintain its shape. This matrix yields low backpressure and high flow rates. One to five cubic centimeters (cc) of the lysine-silica are loaded into a cassette chamber.
- An optimal second chamber housed in the cassette contains a molecular exclusion filtration media. The filtration media is of the type which allows large molecules like the desired biological component to pass through the chamber unimpeded, yet retards the passage of smaller molecular weight molecules like those used for competitive elution of the blood component from the affinity chamber. This results in a molecular separation.
- An optional concentration media chamber in the cassette concentrates the desired biological component solution. The concentration media of the type which is made of cross-linked dextran with liquid absorbing and molecular exclusion properties.
- Additional chambers are optionally included in the cassette to provide solution storage and transfer during the process. Other chambers can provide for the conversion of the desired biological component to its active state and provide a space for the resultant preparation to be assayed for final activity determination.
- The cassette incorporates fluid paths connecting inlet and outlet fluids to the various chambers. The cassette provides the means to valve the flow of fluids to and around the cassette chambers, in addition to controlling fluids to waste and collection.
- The cassette has at least one inlet and one outlet port that has tubing connected to the port. The other end of the tubing is connected to a fluid bag or bags. The inlet tubing allows the fluids, like equilibration buffer, plasma or plasma solution, and/or competitive elution solution, to be brought into the cassette and selectively to the cassette chambers. The outlet tubing allows fluids to be selectively expelled from the cassette and to a fluid waste collection bag.
- The instrument contains a programmable controller of the type which is of electronic, pneumatic, or mechanical (cam) driven or a combination thereof. The controller receives inputs, such as from pushing the start button, and delivers outputs, such as turning a pump on and off, closing and opening valves, and signaling procedure completion.
- With regard to isolation from plasma, blood is first drawn from the patient and the blood plasma is separated from the cellular blood elements using conventional methods, such as centrifugation. After centrifugation, the blood plasma containing the blood component is retained and the cellular blood elements are discarded. The blood plasma is collected into a syringe and transferred to the plasma fluid bag attached to the cassette. A second fluid bag attached to the cassette is loaded with equilibration buffer and a third fluid bag is loaded with an elution buffer.
- The cassette is loaded into the programmable controlled instrument and the fluid bags are hung on their appropriate hooks. The power to the instrument is turned on and the start button is pushed to initialize the controller. The controller now orchestrates the pump, valves, and solenoids to route the correct fluid through the various chambers at the appropriate time and in the appropriate volumes, in order to yield the desired component in a desired concentration in a collection vial at the conclusion of the process.
- A known amount of an activator is then added to the eluted blood component to obtain the desired subcomponent, such as plasmin. The blood component or subcomponent is then used as desired in the surgical or therapeutic procedure.
- A better understanding of the present invention will be had upon reference to the following detailed description, when read in conjunction with the accompanying drawing, wherein like reference characters refer to like parts throughout the several views, and in which:
-
FIG. 1 is an isometric view of the system including the programmable controlled instrument and disposable cassette assembly with attached fluid lines; and -
FIG. 2 is a schematic diagram illustrating the components of the preferred embodiment of the present invention. - The present invention has utility in the processing of a biological fluid to purify a component therefrom. The present invention will be described with respect to automatically separating the blood component plasminogen from blood plasma. The plasminogen is subsequently converted into plasmin and used for surgical and/or therapeutic procedures, such as a vitrectomy and/or vitreous liquefaction. It is appreciated that other blood components are readily separated from blood utilizing the method of the present invention. These other blood components illustratively include fibrin, apolipoprotein, and antibodies.
- While the present invention is detailed herein generally with respect to isolating a component from blood plasma and in particular to purification of plasminogen, it is appreciated that the present invention is also well suited for a variety of other biological component separations. These component separations illustratively include urokinase from urine, nerve growth factor from cerebrospinal fluid, and various components from cell growth media or whole blood.
- With reference then to
FIG. 1 , the automated system to purify and concentrate plasminogen from plasma is shown as 1. System 1 is comprised of two distinct components, aprogrammable instrument 2, and a sterile single-usedisposable cassette assembly 3. Theprogrammable instrument 2 contains a programmable controller having a user interface 20, solenoid and/orpneumatic valve actuators 50, and apump 19. A control panel 20 provides a user interface for programmable controller functions such as to power the instrument, start the preparation process, and monitor the parameters of the process. - The
disposable cassette assembly 3 is typically made of plastic such as polypropylene, polycarbonate, or polyvinyl chloride, and includes acassette 4 that houses at least one internal chamber and has at least oneinlet port 13 and one outlet port 17. Theinlet port 13 is connected to a manifold 21 through inletpump chamber tubing 31. The manifold 21 is in fluid communication with solution containers ofplasma 8,buffer 9, andelution solution 10. Preferably, the solution containers are sterile bags conventional to the blood storage art. The outlet port 17 is in fluid communication with awaste collection bag 12 via outlet tubing 11. Thecassette 4 is placed into a receivingpocket 18 ofprogrammable instrument 2, where it is selectively held therein. -
FIG. 2 shows the preferred system components in schematic form.Cassette 4 is represented by the dotted line box shown inFIG. 2 including arigid housing 54. Thecassette 4 includesaffinity media chamber 22, thechamber 22 enclosingaffinity media 24. An amino acid, such as L-lysine, is affixed to the solid support offered by theaffinity media 24.Affinity media chamber 22 has aninlet 26 and anoutlet 28 such that all liquid injected into theinlet 26 passes through theaffinity media 24 and exits through theoutlet 28. The amino acid L-lysine has a high affinity to selectively adsorb the blood component plasminogen from blood plasma. The lysine (L-lysine monohydrochloride, Sigma Chemical (L-6027)) is bound to the affinity media by conventional methods and then packed into thechamber 22. Preferably, theaffinity media chamber 22 is made of polypropylene with polyethylene frits. It is appreciated other species are readily bound to theaffinity media 24 to selectively adsorb blood components. These species illustratively include antibodies specific to a particular blood component; platelet derived growth factor or other hormones. For example, heparin is a mucopolysaccharide sulfuric acid ester that is found in liver tissue. Heparin is active as a ligand to selectively bind fibroblast growth factor, vascular endothelial growth factor (VEGF), and platelet derived growth factor (PDGF) from cell culture media. Heparin also is active to selectively bind proteins from whole blood or plasma that are involved in the coagulation cascade such as thrombin. - The
chamber 22 typically contains 1 to 5 cc packed volume of affinity media such as L-lysine bound to a rigid support such as epoxy-activated silica beads. Preferably, 2 to 4 cc of affinity medium is utilized herein. Other alternative beads can include a ceramic matrix illustratively including alumina or titania with lysine attached via an epoxy-activated linkage. The affinity media is required to withstand the application of pressure necessary for performing an inventive elution throughput without collapsing. The pressure operative herein is defined to be at least the pressure exerted by a roller pump, syringe pump, or other pump mechanisms against the back pressure induced by the affinity media. Pressures generated herein are typically 1 to 10 atmospheres. The epoxy-activated silica beads operative herein are manufactured by Waters Corporation. Such beads typically have a diameter of 40 μm, a pore size of 50 nm and a binding capacity of 3-7 μmoles of lysine per (ml) of packing material. -
Cassette 4 also has agel media chamber 30 that containsgel filtration media 32, composed of cross-linked dextran beads. Thegel filtration media 32 performs molecular size exclusion. The large blood component plasminogen passes through thegel media 32 comparatively unimpeded while the smaller elution molecules such as epsilon aminocaproic acid enter the pores of the gel media beads and are slowed in traversing the gel media to create a separation. In a preferred embodiment, the gel filtration medium is G-25 fine Sephadex (Amersham Biosciences). It is appreciated that other gel media are operative to filter a desired blood plasma component based upon factors including blood component molecular weight. Thegel media chamber 30 typically contains 1.0 to 2.5 gms ofdry gel beads 32 that swell when hydrated to fill a chamber volume of between 3.5 to 8.8 ml. Preferably, thegel media chamber 30 is made of polypropylene with polyethylene frits. - Alternatively, an ion exchange chromatography media chamber (Sigma Aldrich, Amersham, Waters) is used to molecularly filter the desired blood plasma component based on molecular charge and ionic strength. Employing this technology, the aminocaproic acid molecule forms an ionic bond to the media, displacing a hydrogen ion. The plasminogen then freely passes through the media. The collected fraction may have to be adjusted for pH as a result of the ionic exchange.
- The
cassette 4 also includescollection chamber 34 havingmovable plunger 36.Collection chamber 34 allows the collection of the plasminogen rich fraction from the elution curve exiting thegel media chamber 30. The collected fraction volume typically ranges from 1.0 ml to 5.0 ml for the processing of 0.5 to 2.0 milligrams of plasminogen. - The
cassette 4 also includes aconcentration chamber 38 that includes a filter net 40 (shown inFIG. 2 ), movable plunger 42, andconcentration media 44. Theconcentration media 44 preferably are cross-linked dextran beads. The preferred concentration media is commercially available as dry Sephadex G-50 (Amersham Biosciences), D-salt polyacrylamide gel with a 6,000 Dalton exclusion limit (Pierce Biotechnology), or similar material. The dry quantity ofconcentration media 44 absorbs a known quantity of solvent thereby concentrating the plasminogen in the remaining solvent. Preferably, the quantity of concentrating media is selected to impart a plasminogen concentration of at least two. More preferably, plasminogen is concentrated by a factor of between 3 and 10. For example, 2.6 cc of eluted buffer and plasminogen yields 0.45 ml upon contacting 0.34 grams of dry G-50 Sephadex thereby increasing plasminogen concentration to a final concentration of 0.9-3.0 milligrams per milliliter. The concentrating of a blood component according to the present invention appears to rely on the ability of an immobilized substance such as a Sephadex filtration medium to absorb a well-defined quantity of a solution without absorbing or binding the plasminogen at a higher rate than volume concentration. -
Flexible tubing 48 is used within thecassette 4 to provide fluid communication between the inventive chambers. Optionally,flexible tubing 48 functions as a valve when force is applied. In this way filters, collection vial(s), or test chambers optionally are isolated. Solenoid and/or pneumatic valve actuators are positioned ininstrument 2 such thatpiston rods 50 align withopenings 52 incassette 4 overlying predetermined sections oftubing 48. Theopenings 52 allow thepiston rods 50 to linearly travel and compress theflexible tubing 48 against therigid housing 54 ofcassette 4. Valving action is preferably signaled by the programmable controller. - The inventive process starts with a predetermined amount of blood, for example 48 cc, being removed from the patient in any conventional fashion such as by syringe or vacuum collection tubes containing an anticoagulant. The amount of blood removed from the patient varies, depending upon the final amount of the desired blood component required.
- The blood plasma is separated from the cellular blood elements in any conventional fashion, such as by centrifuging. In the preferred embodiment of the invention, the blood is centrifuged at 1000 g for ten minutes at 25° C. The plasma is then collected in a sterile syringe. Typically, 10 to 30 cc of plasma is collected. For a vitrectomy, preferably 20 to 25 cc of plasma is collected.
- The plasma is then transferred into a container, preferably a
fluid bag 8 ofdisposable cassette assembly 3.Fluid bag container 9 is filled with a sterile equilibrium buffer plasma, such isotonic potassium phosphates buffer, balanced salt solution, or a dilute balanced salt solution, in a volume of between 50 ml and 250 ml.Fluid bag 10 is filled with a competitive elution solution, such as epsilon aminocaproic acid and potassium phosphate buffer, in volume of between 5 ml and 20 ml and a concentration of between 0.5 mg/ml and 10.0 mg/ml. Optionally, the plasma and/or elution solution remain in syringes that are connected to the tubing in lieu of a fluid bag. -
Disposable cassette assembly 3 is loaded into theprogrammable instrument 2.Solution bags instrument 2.Tubing lines slots Manifold 21 is placed inrecess 66.Pump chamber 31 is fed intoroller pump 19 andcassette 4 is locked in place intoinstrument pocket 18. Outlet tube 11 is placed inslot 58 andfluid bag 12 is positioned to collect the fluid waste transmitted by outlet tube 11. - In operation, the inventive sequence of events begins with
instrument 2 being energized through the user interface control panel 20. Table 1 provides a step-by-step breakdown of the preparation process indicating fluid movements and valving of the present invention with respect toFIGS. 1 and 2 . Table 1 presumes prior blood draw and fluid bag filling.TABLE 1 Pinch valve sequence for blood component isolation PINCH VALVE OPERATION (O = Open, X = Closed) STEP FLUID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 1. AC flush, GC hydrate buffer O O O O X X X X X X X X X X X & flush, to Waste 2. AC plasma, to Waste plasma X O X X O X O X X X X X X X X 3. AC plasma flush, to buffer O O X X X X O X X X X X X X X Waste 4. Elute & stage protein, elution X O O O X O X X X X X X X X X to Waste 5. Collected fraction to elution X O O X X O X X X X O O X O O collection syringe 6. Collection fraction to buffer O X X X X X X X O X O X O X O concentrator 7. Concentrator to vial buffer O X X X X X X X O O X X X O X - Step 1 involves the delivery of equilibrium buffer for pre-washing of the affinity media, hydrating and washing the gel media, and delivering the passed fluids to waste. The buffer is drawn from
fluid bag 9 through tubing 6 and through open valve V1. The buffer flows intomanifold 21 and throughpump chamber 31 driven bypump 19, through open valve V2 and intoaffinity media chamber 22. The buffer continues through theaffinity media chamber 22 pre-washing and wetting theaffinity media 24, then exitingchamber 22 flowing through open valve V3 and into gelfiltration media chamber 30. The buffer is absorbed by thedry gel media 32, swelling the beads and expanding to fillchamber 30 and washing of thegel media 32 after swelling. Buffer continues to be pumped throughchamber 30 until it exits and flows through open valve V4, through tubing 11 and intowaste fluid bag 12. All other valves in the system are closed at this time. Buffer continues to be pumped through at Step 1 until a predetermined time and/or volume has been reached and the programmable controller stops thepump 19 and switches the valve sequence toStep 2. -
Step 2 delivers the plasma through theaffinity media 24, where the lysine ligand selectively binds to the desired blood component, which for illustrative purposes is plasminogen. The plasma is draw out offluid bag 8 throughtubing 7 and through open valve V5. The plasma flows intomanifold 21 and throughpump chamber 31 driven bypump 19, through open valve V2 and intoaffinity media chamber 22. The plasma flows out ofchamber 22 and through open valve V7. Plasma continues to flow out through tubing 11 and intowaste fluid bag 12. All other valves in the system are closed at this time. Plasma continues to be pumped through atStep 2 until a predetermined time, volume, and/or a sensor determined condition has been reached. Then, the programmable controller stops the pump and switches the valve sequence toStep 3. -
Step 3 delivers equilibrium buffer to theaffinity media chamber 22 to wash the plasma from thechamber 22 along with any unbound proteins, leaving only the bound blood component, namely plasminogen. Buffer is drawn out offluid bag 9 through tubing 6 and through open valve V1. The buffer flows intomanifold 21 and throughpump chamber 31 driven bypump 19, through open valve V2 and intoaffinity media chamber 22. The buffer flows out ofchamber 22 and through open valve V7. The buffer continues to flow out through tubing 11 and intowaste fluid bag 12. All other valves in the system are closed duringStep 3 as detailed in Table 1. Buffer continues to be pumped through atStep 3 until a predetermined time, volume, and/or a sensor determined condition has been reached. Then, the programmable controller stops the pump and switches the valve sequence toStep 4. -
Step 4 involves the displacement of the equilibrium buffer from theaffinity media chamber 22 andgel chamber 30, and the elution of the plasminogen from theaffinity media 24 with a competitive binding solution, such as epsilon aminocaproic acid also occurs in the course ofStep 4. Elution solution is withdrawn fromfluid bag 10 throughtubing 5 and through open valve V6. The elution solution flows intomanifold 21 and throughpump chamber 31 driven bypump 19, through open valve V2 and intoaffinity media chamber 22. The elution solution continues through theaffinity media chamber 22 flushing the buffer and unbinding the plasminogen, then exitingchamber 22 flowing through open valve V3 and into gelfiltration media chamber 30. The solution is molecularly filtered by thegel filtration media 32 by allowing the large molecular weight plasminogen to flow through and the low molecular weight elution molecule to be retarded by entering the pores of the swollen gel beads. Elution solution continues to be pumped throughgel media chamber 30 until it exits and flows through open valve V4, through tubing 11 and intowaste fluid bag 12. All other valves in the system are closed at this time. Elution solution continues to be pumped through atStep 4 until a predetermined time, volume, and/or a sensor determined condition has been reached and the programmable controller stops thepump 19 and switches the valve sequence toStep 5. At this point in the process the controller preferably allows a dwell time between the elution solution to elute more of the plasminogen from the lysine. Dwell time appears to increase the eluted peak height and therefore the eluted protein. The dwell time is in the range of 5 to 30 minutes. -
Step 5 involves the continuation of the plasminogen elution process, with preferably the elution curve staged such that the highest concentration of plasminogen can be collected in a single fraction. It is appreciated that other collection profiles are possible according to the present invention. Elution solution is withdrawn fromfluid bag 10 throughtubing 5 and through open valve V6. The elution solution flows intomanifold 21 and throughpump chamber 31 driven bypump 19, through open valve V2 and intoaffinity media chamber 22. The elution solution will continue through the affinity media chamber unbinding the plasminogen, then exitingchamber 22 flowing through open valve V3 and into gelfiltration media chamber 30. Gelfiltration media chamber 30 continues to separate the plasminogen from the eluent. The plasminogen solution exitschamber 30 and flows through open valve V12 and intocollection chamber 34. The pressure of the incoming fluid displacesplunger 36 ofchamber 34 while valves V1, V14, and V15 are open so that the air in the system moved by the displacedcollection plunger 36 exits the system throughfilter 60. Elution solution continues to be pumped through atStep 5 until a predetermined time, volume, and/or a sensor determined condition has been reached and the programmable controller stops the pump and switches the valve sequence to Step 6. - It is appreciated that
Steps 4 and/or 5 can be independently controlled by monitoring the component concentration exiting gelfiltration media chamber 30. A spectrophotometric light generator and detector at a wavelength overlapping a component absorption, which for plasminogen is illustratively 280 nm, not shown, is adapted to detect the change in absorption in the fluid stream. The absorption signal correlating to the protein concentration. Optionally, the controller is programmed to switch the sequence of the valves when a predetermined protein concentration is reached, in order to insure consistent capture of the protein peak of the elution profile. - Step 6 involves the moving of the collected fraction volume of, for example, approximately 2.6 ml of plasminogen solution from
collection chamber 34 toconcentration chamber 38. The concentration of the plasminogen solution will be increased by removing a percentage of the aqueous from the solution byconcentration media 44. Buffer is drawn fromfluid bag 9 through tubing 6 and through open valve V1. The buffer flows intomanifold 21 and throughpump chamber 31 driven bypump 19, and through open valves V9 and V11. The buffer is used as a hydraulic fluid to displaceplunger 36 incollection chamber 34 and move the plasminogen solution out of thechamber 34. When the pressure reaches a preselected level, the plasminogen solution moves out ofcollection chamber 34 through open valve V13 and intoconcentration chamber 38, displacing plunger 42. At the same time valve V15 is open so that the air moved by displaced plunger 42 ofchamber 38 is vented from the system throughfilter 60. -
Step 7 involves the movement of a concentrated volume of approximately 0.5 ml, based on 2.6 ml plasminogen volume in Step 6 of plasminogen solution from theconcentration chamber 38 tofinal collection vial 62.Collection vial 62 is optionally incorporated intocassette 4 or may be added to the system during setup. Buffer is drawn fromfluid bag 9 through tubing 6 and through open valve V1. The buffer flows intomanifold 21 and throughpump chamber 31 driven bypump 19, and through open valves V9 and V14. The buffer is being used as a hydraulic fluid to displace plunger 42 inchamber 38 and move the concentrated plasminogen solution out of thechamber 38. When the pressure reaches a preselected level, the plasminogen solution moves out ofcollection chamber 38 through open valve V10, throughfilter 64, through piercingdevice 66 and intocollection vial 62. - The collected plasminogen is available for a variety of uses and may be converted or activated to plasmin by the addition of an activator such as streptokinase or urokinase. Alternatively the activator is placed in the vial prior to attaching it to
cassette 4, so conversion occurs as the final concentrated plasminogen is expressed into thevial 62. The conversion of plasminogen to plasmin occurs in 5-15 minutes at room temperature. The plasmin is now ready for use such as for injection into the eye, or other surgical or research applications. - In an alternate biological component separation, urokinase is isolated from urine as an activator of plasminogen to the enzyme plasmin. A disposable cassette with a single chamber contains affinity media such as an antibody or antibody fraction bound to a rigid support, such as epoxy-activated silica bead. The antibody illustratively including goat anti-human urokinase, Monosan PS075 (Sanbio, The Netherlands). The affinity media is washed with buffer then urine is pumped through the affinity chamber. The urokinase selectively binds to the antibody and then the affinity chamber is flushed of the residual urine and urine constituents. The elution is performed with an acidic citrate buffer that is introduced to the affinity chamber to unbind the urokinase. The peak of the eluted urokinase is collected in a collection vial where neutralization optionally occurs if desired for a particular purpose.
- Active plasmin quantification involves conventional techniques such as placing a drop of plasmin solution onto a piece of filter paper treated with a synthetic substrate (D-val-leu-lys-pnitroanilide dihydrochloride, Sigma V-0882). Cleavage of the substrate produces a bright yellow color the intensity of which correlates with the presence of plasmin. Alternatively, a spectrophotometric assay based upon the difference between initial and final optical absorbance multiplied by a constant for the cleavage of the synthetic substrate (D-val-leu-lys-pnitroanilide dihydrochloride) measured at a wavelength of 405 nanometers, is employed. Absorption studies, for example, are performed by adding 950 μl of lysine buffer and 250 μl of substrate to a cuvette and zeroing the initial absorbance. 50 μl of plasmin is then added and the absorbance one minute later is measured as the final absorbance.
- The above-described separation of the blood component plasminogen and its subsequent conversion into plasmin is accomplished in the matter of tens of minutes in the operating room or laboratory. The automation allows several plasmin preparations to be performed simultaneously by a single clinical technician. The sterile single use cassette assembly provides a closed system of biologic preparation.
- Patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are incorporated herein by reference to the same extent as if each individual patent or publication was specifically and individually incorporated herein by reference.
- It will, of course, be understood that different biologic components utilizing different binding agents and different releasing agents may alternatively be used without deviation from the spirit or scope of the present invention. Having described our invention, many modifications thereto will become apparent to those skilled in the art to which it pertains without deviation from the spirit of the invention as defined by the scope of the appended claims.
Claims (25)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/635,181 US7001513B2 (en) | 2003-08-06 | 2003-08-06 | Automated processing of a biological component |
PCT/US2004/025413 WO2005014139A1 (en) | 2003-08-06 | 2004-08-06 | Automated processing of a biological component |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/635,181 US7001513B2 (en) | 2003-08-06 | 2003-08-06 | Automated processing of a biological component |
Publications (2)
Publication Number | Publication Date |
---|---|
US20050029181A1 true US20050029181A1 (en) | 2005-02-10 |
US7001513B2 US7001513B2 (en) | 2006-02-21 |
Family
ID=34116178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/635,181 Expired - Fee Related US7001513B2 (en) | 2003-08-06 | 2003-08-06 | Automated processing of a biological component |
Country Status (2)
Country | Link |
---|---|
US (1) | US7001513B2 (en) |
WO (1) | WO2005014139A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100193413A1 (en) * | 2007-07-09 | 2010-08-05 | Mbonline Gmbh | Device for monitoring water for microbial germs |
US20110143427A1 (en) * | 2009-12-16 | 2011-06-16 | General Electric Company | High-throughput methods and systems for processing biological materials |
JP2018518355A (en) * | 2015-04-07 | 2018-07-12 | テルモ ビーシーティー、インコーポレーテッド | Bead removal |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9575087B2 (en) * | 2012-09-06 | 2017-02-21 | Parker-Hannifin Corporation | Risk-managed, single-use, pre-calibrated, pre-sterilized sensors for use in bio-processing applications |
WO2009017614A1 (en) * | 2007-08-02 | 2009-02-05 | Millipore Corporation | System and apparatus for processing fluid samples |
DE102008015387B4 (en) * | 2008-03-20 | 2019-01-10 | Sartorius Stedim Biotech Gmbh | Pre-sterilizable filtration system for single use |
US9974902B2 (en) * | 2013-08-30 | 2018-05-22 | Kpr U.S. Llc | Feeding rate compensated pump and related methods therefor |
LT3215601T (en) | 2014-11-05 | 2020-08-25 | Juno Therapeutics, Inc. | Methods for transduction and cell processing |
USD812741S1 (en) * | 2015-08-14 | 2018-03-13 | Mequ A/S | Blood transfusion and sampling apparatus |
US11207452B2 (en) * | 2019-08-30 | 2021-12-28 | Fresenius Medical Care Holdings, Inc. | Multi-lumen tube assemblies for medical fluid pumping systems |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3996017A (en) * | 1972-11-24 | 1976-12-07 | Kaiser Rudolph E | Cassette separating column system for chromatography |
US4911807A (en) * | 1989-09-05 | 1990-03-27 | Bio-Rad Laboratories, Inc. | Fractionation and sample loading by cassette in capillary electrophoresis |
US5193990A (en) * | 1986-03-04 | 1993-03-16 | Deka Products Limited Partnership | Fluid management system with auxiliary dispensing chamber |
US5260028A (en) * | 1988-02-22 | 1993-11-09 | Astle Thomas W | Method and apparatus for effecting solid phase extraction |
US5372695A (en) * | 1993-05-07 | 1994-12-13 | Applied Biosystems, Inc. | Application specific capillary electrophoresis |
US5989423A (en) * | 1993-03-03 | 1999-11-23 | Deka Products Limited Partnership | Disposable cassette, delivery set and system for peritoneal dialysis |
US6325775B1 (en) * | 1999-09-03 | 2001-12-04 | Baxter International Inc. | Self-contained, transportable blood processsing device |
US6582386B2 (en) * | 2001-03-06 | 2003-06-24 | Baxter International Inc. | Multi-purpose, automated blood and fluid processing systems and methods |
US6605223B2 (en) * | 2000-06-20 | 2003-08-12 | Medicept, Inc. | Blood component preparation (BCP) device and method of use thereof |
US6712963B2 (en) * | 2002-06-14 | 2004-03-30 | Scilog, Llc | Single-use manifold for automated, aseptic transfer of solutions in bioprocessing applications |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5683916A (en) * | 1988-10-31 | 1997-11-04 | Hemasure Inc. | Membrane affinity apparatus and purification methods related thereto |
DE3917840A1 (en) * | 1989-06-01 | 1990-12-06 | Bodenseewerk Perkin Elmer Co | ARRANGEMENT FOR ENLARGING SAMPLES FOR SPECTROSCOPIC PURPOSES IN FLOW INJECTION ANALYSIS |
-
2003
- 2003-08-06 US US10/635,181 patent/US7001513B2/en not_active Expired - Fee Related
-
2004
- 2004-08-06 WO PCT/US2004/025413 patent/WO2005014139A1/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3996017A (en) * | 1972-11-24 | 1976-12-07 | Kaiser Rudolph E | Cassette separating column system for chromatography |
US5193990A (en) * | 1986-03-04 | 1993-03-16 | Deka Products Limited Partnership | Fluid management system with auxiliary dispensing chamber |
US5260028A (en) * | 1988-02-22 | 1993-11-09 | Astle Thomas W | Method and apparatus for effecting solid phase extraction |
US4911807A (en) * | 1989-09-05 | 1990-03-27 | Bio-Rad Laboratories, Inc. | Fractionation and sample loading by cassette in capillary electrophoresis |
US5989423A (en) * | 1993-03-03 | 1999-11-23 | Deka Products Limited Partnership | Disposable cassette, delivery set and system for peritoneal dialysis |
US5372695A (en) * | 1993-05-07 | 1994-12-13 | Applied Biosystems, Inc. | Application specific capillary electrophoresis |
US6325775B1 (en) * | 1999-09-03 | 2001-12-04 | Baxter International Inc. | Self-contained, transportable blood processsing device |
US6605223B2 (en) * | 2000-06-20 | 2003-08-12 | Medicept, Inc. | Blood component preparation (BCP) device and method of use thereof |
US6582386B2 (en) * | 2001-03-06 | 2003-06-24 | Baxter International Inc. | Multi-purpose, automated blood and fluid processing systems and methods |
US6712963B2 (en) * | 2002-06-14 | 2004-03-30 | Scilog, Llc | Single-use manifold for automated, aseptic transfer of solutions in bioprocessing applications |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100193413A1 (en) * | 2007-07-09 | 2010-08-05 | Mbonline Gmbh | Device for monitoring water for microbial germs |
US8518246B2 (en) * | 2007-07-09 | 2013-08-27 | Mbonline Gmbh | Device for monitoring water for microbial germs |
US20110143427A1 (en) * | 2009-12-16 | 2011-06-16 | General Electric Company | High-throughput methods and systems for processing biological materials |
US9034280B2 (en) | 2009-12-16 | 2015-05-19 | General Electric Corporation | High-throughput methods and systems for processing biological materials |
US10088399B2 (en) | 2009-12-16 | 2018-10-02 | General Electric Company | High-throughput methods and systems for processing biological materials |
JP2018518355A (en) * | 2015-04-07 | 2018-07-12 | テルモ ビーシーティー、インコーポレーテッド | Bead removal |
Also Published As
Publication number | Publication date |
---|---|
WO2005014139A1 (en) | 2005-02-17 |
US7001513B2 (en) | 2006-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9526821B2 (en) | Blood separation and concentration system | |
US7001513B2 (en) | Automated processing of a biological component | |
US7987995B2 (en) | Method and apparatus for preparing platelet rich plasma and concentrates thereof | |
JPH0451185B2 (en) | ||
JP2008538514A (en) | Integrated system for collecting, processing and transplanting cell subsets including adult stem cells for regenerative medicine | |
JPH0757177B2 (en) | Specific cell separation device and specific cell separation method | |
JPS6145773A (en) | Material and apparatus for purifying body fluids | |
CA1194395A (en) | Device for the detection of bacteria, fungi and viruses in blood | |
EP1137465B1 (en) | Method for purification of a blood component | |
US8454907B2 (en) | Growth factor extractor | |
KR101627408B1 (en) | Device and method for extractioning high rich plasma | |
JP2006160731A (en) | Blood ingredient-recovering apparatus | |
US6855263B2 (en) | Rapid process for purification and concentration of plasmin | |
JPH0489500A (en) | Method for purifying substance by affinity chromatography and apparatus for purification | |
US20210220818A1 (en) | Method for the capture and isolation of disease material from flowing matter | |
CN216236791U (en) | Tandem chromatographic column for purifying tag protein | |
CN109321457A (en) | A kind of equipment and its application preparing cell | |
EP0358758A1 (en) | B lymphocyte separating material and body fluid clarifying material | |
WO1991010492A1 (en) | Apparatus and method for affinity separation | |
Marcus et al. | A New Immunoadsorbent for Hemoperfusion: Agarose-Polyacrolein Microspheres Beads I. In Vitro Studies | |
CN210583236U (en) | Clinical continuous blood component centrifugal separator | |
CN219558256U (en) | Circulation feedback type circulating tumor cell external magnetic filter device | |
JPH0372309B2 (en) | ||
CA1325172C (en) | Device for plasma modification -- composition and remodeling | |
JPS63132665A (en) | Apparatus for recovery of protein in blood |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NUVUE TECHNOLOGIES, INC., NEW HAMPSHIRE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BELL, CRAIG J.;REEL/FRAME:014492/0749 Effective date: 20030806 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: THROMBOGENICS N.V., BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NUVUE TECHNOLOGIES, INC.;REEL/FRAME:027807/0598 Effective date: 20120302 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.) |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.) |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20180221 |